Cadonilimab Antibody

SKU: orb1980727

Description

Cadonilimab (AK104) is a tetravalent PD-1/CTLA-4 bispecific humanised antibody that activates T cells by enhancing IL-2 and IFN-γ secretion while reducing pro-inflammatory cytokine secretion (e.g., IL-6, IL-8). It offers low toxicity and high affinity, making it suitable for metastatic cervical, gastric, hepatic, and pulmonary cancers, pancreatic cancer, and oesophageal squamous cell carcinoma.

Research Area

Cell Biology, Immunology & Inflammation, Neuroscience

Images & Validation

−

Key Properties

−

CAS Number	2394841-59-7
Purity	95.00%
Target	COX,Immunology/Inflammation related,IL Receptor,PD-1/PD-L1

Bioactivity

−

In Vivo

Methods the NCG mouse subcutaneous xenograft model (MGC803 cell line) was employed, with cadonilimab administered via intraperitoneal injection the dosing regimen was as follows the first three doses at 1 mg/kg (initiated on day 4 post-grouping, twice weekly for three consecutive weeks), followed by Six doses at 5 mg/kg (twice weekly for Six consecutive weeks). Result: Cadonilimab demonstrated significant anti-tumor efficacy when combined with chemotherapy, but exhibited limited effectiveness when used alone

Storage & Handling

−

Storage	Maintain refrigerated at 2-8°C for up to 2 weeks. For long term storage store at -20°C in small aliquots to prevent freeze-thaw cycles.
Disclaimer	For research use only

Alternative Names

−

BTG502

Quality Guarantee

Explore bioreagents carefree to elevate your research. All our products are rigorously tested for performance. If a product does not perform as described on its datasheet, our scientific support team will provide expert troubleshooting, a prompt replacement, or a refund. For full details, please see our Terms & Conditions and Buying Guide. Contact us at support@biorbyt.com.

Quick Database Links

Gene Symbol

COX,Immunology/Inflammation related,IL Receptor,PD-1/PD-L1

Documents Download

Datasheet

Product Information

Download

Request a Document

Protocol Information

Find More Protocols